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BACKGROUND: Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is infrequently offered to
older individuals. This study determined if there are fit older patients with high-risk disease who may benefit from chemotherapy.
METHODS: A multicentre, prospective, observational study was performed to determine chemotherapy (±trastuzumab) usage and
survival and quality-of-life outcomes in EBC patients aged ≥70 years. Propensity score-matching adjusted for variation in baseline
age, fitness and tumour stage.
RESULTS: Three thousands four hundred sixteen women were recruited from 56 UK centres between 2013 and 2018. Two
thousands eight hundred eleven (82%) had surgery. 1520/2811 (54%) had high-risk EBC and 2059/2811 (73%) were fit.
Chemotherapy was given to 306/1100 (27.8%) fit patients with high-risk EBC. Unmatched comparison of chemotherapy versus no
chemotherapy demonstrated reduced metastatic recurrence risk in high-risk patients(hazard ratio [HR] 0.36 [95% CI 0.19–0.68]) and
in 541 age, stage and fitness-matched patients(adjusted HR 0.43 [95% CI 0.20–0.92]) but no benefit to overall survival (OS) or breast
cancer-specific survival (BCSS) in either group. Chemotherapy improved survival in women with oestrogen receptor (ER)-negative
cancer (OS: HR 0.20 [95% CI 0.08–0.49];BCSS: HR 0.12 [95% CI 0.03–0.44]).Transient negative quality-of-life impacts were observed.
CONCLUSIONS: Chemotherapy was associated with reduced risk of metastatic recurrence, but survival benefits were only seen in
patients with ER-negative cancer. Quality-of-life impacts were significant but transient.
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BACKGROUND
In 2014–2016 over 18,500 women per year aged ≥70 years were
diagnosed with breast cancer in the UK, representing 34% of all
diagnoses.1 Breast cancer survival is worse in older patients2 who
have not experienced similar outcome improvements compared
with younger individuals in the past three decades.3 This may
reflect late presentation, more comorbidities or undertreatment.
Significant treatment variations between centres are frequently
reported in older adults.4,5 However, interpreting such data can be
challenging without information on fitness, which may mitigate
treatment benefits, due to competing mortality risks and
increased treatment-related toxicity.
Chemotherapy benefit in older women is controversial. While
there have been many high-quality randomised clinical trials
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(RCTs) to evaluate the impact of systemic chemotherapy, the
majority of trials excluded or recruited poorly amongst older
patients, and tended to enrol fitter individuals.6 This reflects
clinicians’ and patients’ toxicity concerns and reticence from
trialists about diluting the study power by introducing higher
morbidity rates and competing causes of death in less fit older
patients.
Older adults derive less benefit from chemotherapy compared to
younger patients. Benefit is present between the ages of 70 and 80,
although data for women aged over 80 years are scarce.7 The
Bridging the Age Gap study was designed to recruit a large, real-
world, cohort of older women with breast cancer including detailed
baseline fitness data and information about the cancer, treatment
received and outcomes. The objectives of this study analysis were to
determine health status-stratified outcomes for EBC patients aged
≥70 according to whether they received guideline concordant or
non-concordant care with a particular focus on chemotherapy use.
In this paper, the age- and risk-stratified patterns of receipt of
adjuvant systemic therapy are described in older EBC patients, with




Bridging the Age Gap is a prospective multicentre, observational
cohort study. Patients were recruited from 56 UK centres in
England and Wales (Supplementary Table 1). Eligible patients were
women ≥70 years at diagnosis of primary operable invasive breast
cancer (TNM stages: T1-3 (plus some T4b), N0-1, M0). Those
unsuitable for surgery or with previous EBC within five years were
not eligible.
Baseline data collection
Patients were recruited at the time of EBC diagnosis and before
commencing treatment and could participate at three levels: full,
partial (no requirement to complete quality of life [QoL]
assessments) or by proxy (simple third-party data collection for
those with cognitive impairment).
Baseline data were collected about the primary tumour
including; cancer type, grade, nodal status, tumour size, oestrogen
(ER), progesterone (PR) and human epidermal growth factor
receptor 2 (HER2) status. Staging was performed if clinically
indicated. Surgical, radiotherapy and systemic therapy data were
collected.
At baseline, patients underwent assessments using validated
tools including: comorbidities (Charlson comorbidity index [CCI]),8
nutrition (Abridged Patient Generated Subjective Global Assess-
ment [aPG-SGA]),9,10 functional status (Activities of Daily Living
[ADL]),11 advanced functional status (Instrumental Activities of
Daily Living [IADL]),12 dementia (Mini Mental State Examination
[MMSE]),13 Eastern Cooperative Oncology Group Performance
Status (ECOG PS) and medication list.
Quality-of-life was assessed using the EuroQol-5D-5L (EQ-5D-
5L).14 Assessments on the European Organisation for the Research
and Treatment of Cancer QoL Questionnaire (EORTC-QLQ)-C30,15
EORTC-QLQ-BR23,16 EORTC-QLQ-ELD1517 were also collected but
are presented elsewhere.18
Follow-up and outcomes
Patients were followed up at 6 weeks, and 6, 12, 18 and
24 months. Survival outcomes (date and cause of death) were
obtained at 52 months median follow-up from the UK cancer
registry. All patients were assessed for recurrence and QoL at each
visit. Complications were categorised using the Common Termi-
nology Criteria for Adverse Events system (CTCAE v4.0).
Chemotherapy-related mortality was defined as death within
30 days of chemotherapy or if chemotherapy was documented as
a contributing cause. Deaths were categorised as disease related
or other causes. Deaths were reviewed by the chief investigator
blind to treatment decisions. Deaths were classified as disease
related if the death was related to the initial breast cancer.
Patients for whom the cause could not be established were
excluded from cause-specific analyses.
Statistical analyses
Analyses were performed in IBM SPSS statistics version 24 and R
version 3.6.3.19 A p < 0.05 was considered statistically significant.
The relationships between systemic therapy use and tumour
and patient characteristics were evaluated using uni- and multi-
variable logistic regression. High-risk EBC was defined if any of the
following criteria were present: node-positive, ER-negative, HER2
positive, grade 3 or Recurrence Score ≥25. (Supplementary
Table 2a). Additional analyses were conducted in patients with
ER-negative and HER2-positive tumours, where the benefits from
chemotherapy might be anticipated. Fitness was defined based on
geriatric assessments and categorised into fit, vulnerable and frail
according to a cumulative score including measures of functional
status, comorbidities, polypharmacy, nutritional status and cogni-
tive status (Supplementary Table 2b).
Both overall survival (OS) and breast cancer-specific survival
(BCSS) were compared in treated and untreated patients. A Cox
proportional hazards model was fitted using regression-based
adjustment based on covariates of: treatment; age; categories of
aPG-SGA, ADL, IADL, CCI, MMSE, ECOG, medications and Notting-
ham Prognostic Index (NPI)20 and HER2 for all high-risk patients.
Hazard ratios (HR) and corresponding 95% confidence intervals
(CIs) were calculated.
A propensity score adjustment among sufficiently similar high-
risk patients was fitted using a Cox model with a shared frailty
term (or random effect) for matched patients. Participants were
matched exactly on NPI category and HER2 status, and logistic
regression was used to calculate propensity scores for treatment
in relation to age, aPG-SGA category, ADL category, IADL category,
MMSE category, CCI category, ECOG PS category and number of
medications. The ratio and calliper widths of the propensity scores
were chosen following examination of the propensity score
overlaps for several combinations of ratios and callipers. A 1:3
ratio for chemotherapy versus no chemotherapy and a calliper of
0.25 times the propensity scores’ standard deviation was used to
ensure participants were closely matched whilst retaining as many
patients as possible.
The QoL questionnaires were scored according to the EQ-5D-
5L User Guide (Version 3.0).21 Missing data were managed
accordingly. The QoL analysis included only patients with high-
risk EBC as detailed in Supplementary Table 2a and where
questionnaires were available. The mean difference (95% CI) of
the domain scores at each time-point, adjusted for baseline
scores, was calculated with linear regression models for high-risk
participants. Propensity score-matching was also performed, as
detailed above, to compare the EQ-5D-5L usual activities score
in a matched cohort receiving chemotherapy versus patients not
receiving it.
RESULTS
Between January 2013 and June 2018, 3456 women were
recruited from 56 centres in England and Wales. This analysis
was restricted to the 2811 women who underwent surgery within
6 months of diagnosis (STROBE diagram [Fig. 1]).22 Patients’
characteristics according to geriatric assessments, tumour char-
acteristics, postoperative histology and surgery performed are
shown in Table 1.
Of the 2811 patients, 397 (14.1%) received chemotherapy (365
[92%] in the adjuvant setting, 30 [8%] in neoadjuvant setting, and
2 [0.5%] unknown). Of those 380 patients for whom the
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chemotherapy regimen received was known, 132 (34.7%) received
an anthracycline-taxane combination, 124 (32.6%) a taxane
(without anthracycline), 123 (32.4%) an anthracycline and 1 CMF.
332 patients (11.8%) had HER2-positive EBC. Of these patients, 150
(45.1%) received chemotherapy plus trastuzumab, 13 (3.9%)
trastuzumab without chemotherapy, and 9 (2.7%) chemotherapy
without trastuzumab. Overall, 1753/2811 (62.4%) patients received
radiotherapy and 2239/2354 (95.1%) ER-positive patients received
endocrine therapy.
Chemotherapy receipt according to tumour and patient
characteristics is shown in Supplementary Tables 3 and 4.
Univariate and multivariate analyses are shown in Table 2.
Younger, less dependent patients with high-risk tumours and with
fewer comorbidities were more likely to receive chemotherapy.
High-risk tumours were present in 1520 (54%) patients and 376/
1520 (25%) received chemotherapy compared with 21/1291
(1.6%) of patients with non-high-risk tumours (Table 3a). 2059
patients (73%) were fit and 752 vulnerable or frail (27%) (Table 3b).
Of those who were fit, 1100 also had high-risk EBC, and of these
patients 306 (28%) received chemotherapy (Table 3c).
At a median follow-up of 52 months, mortality status was
available for 98% (1495/1520) of high-risk patients (371 in the
chemotherapy group, 1124 in the no chemotherapy group).
Chemotherapy was associated with a longer OS, but the difference
was not statistically significant when adjusted for other covariates
(unadjusted HR 0.55 [95% CI 0.40–0.73, p < 0.001] and adjusted HR
0.87 [95% CI 0.58–1.28, p= 0.469] (Fig. 2a). In a propensity score-
























Not included in the analyses (n = 40)
- Patient withdrew consent (n = 14)
- Ineligible (n = 22)
- Administrative reasons (n = 4)
Reasons not consented (n = 2137):
- Patient/consultee not interested or lack of time 
(n = 645)
- Other (n = 889)
- Not specified (n = 560)
- Ineligible (n = 43)
Fig. 1 STROBE diagram. STROBE flow diagram for the chemotherapy vs no chemotherapy analyses.
Bridging The Age Gap: observational cohort study of effects of. . .
A Ring et al.
3
Table 1. Baseline tumour, patient and treatment characteristics by age.
70–74 75–79 80–84 ≥85 All
N= 1173 N= 899 N= 506 N= 233 N= 2811
Participation level Full 926 (78.9%) 674 (75.0%) 368 (72.7%) 143 (61.4%) 2111 (75.1%)
Partial 225 (19.2%) 209 (23.2%) 123 (24.3%) 64 (27.5%) 621 (22.1%)
Consultee 22 (1.9%) 16 (1.8%) 15 (3.0%) 26 (11.2%) 79 (2.8%)
Main side Right 535 (45.6%) 418 (46.5%) 247 (48.8%) 105 (45.1%) 1305 (46.4%)
Left 638 (54.4%) 481 (53.5%) 259 (51.2%) 128 (54.9%) 1506 (53.6%)
Tumour size (mm) ≤20 649 (55.3%) 371 (41.3%) 184 (36.4%) 75 (32.2%) 1279 (45.5%)
21–50 439 (37.4%) 439 (48.8%) 271 (53.6%) 136 (58.4%) 1285 (45.7%)
>50 66 (5.6%) 66 (7.3%) 40 (7.9%) 16 (6.9%) 188 (6.7%)
Unknown 19 (1.6%) 23 (2.6%) 11 (2.2%) 6 (2.6%) 59 (2.1%)
Tumour size (mm) n 1154 876 495 227 2752
Mean (SD) 23.1 (17.7) 26.5 (16.2) 27.6 (15.4) 28.8 (15.7) 25.4 (16.8)
Median (IQR) 19.0 (12.0, 28.0) 22.0 (16.0, 32.0) 25.0 (17.0, 35.0) 25.0 (19.0, 35.0) 21.0 (15.0, 31.0)
Min, Max 0, 210 0, 155 0, 120 7, 120 0, 210
Nodal status pN0-1mi 867 (73.9%) 573 (63.7%) 326 (64.4%) 147 (63.1%) 1913 (68.1%)
pN1 212 (18.1%) 223 (24.8%) 117 (23.1%) 60 (25.8%) 612 (21.8%)
pN2 46 (3.9%) 54 (6.0%) 36 (7.1%) 11 (4.7%) 147 (5.2%)
pN3 29 (2.5%) 25 (2.8%) 16 (3.2%) 8 (3.4%) 78 (2.8%)
pNx 19 (1.6%) 24 (2.7%) 11 (2.2%) 7 (3.0%) 61 (2.2%)
Grade Grade 1 199 (17.0%) 110 (12.2%) 47 (9.3%) 25 (10.7%) 381 (13.6%)
Grade 2 635 (54.1%) 482 (53.6%) 255 (50.4%) 113 (48.5%) 1485 (52.8%)
Grade 3 311 (26.5%) 278 (30.9%) 190 (37.5%) 86 (36.9%) 865 (30.8%)
Unknown 28 (2.4%) 29 (3.2%) 14 (2.8%) 9 (3.9%) 80 (2.8%)
Histology Ductal NST 761 (64.9%) 567 (63.1%) 341 (67.4%) 146 (62.7%) 1815 (64.6%)
Lobular carcinoma 164 (14.0%) 128 (14.2%) 58 (11.5%) 25 (10.7%) 375 (13.3%)
Tubular carcinoma 21 (1.8%) 5 (0.6%) 3 (0.6%) 0 (0.0%) 29 (1.0%)
Mucinous carcinoma 18 (1.5%) 28 (3.1%) 12 (2.4%) 13 (5.6%) 71 (2.5%)
Other 110 (9.4%) 83 (9.2%) 53 (10.5%) 20 (8.6%) 266 (9.5%)
Unknown 99 (8.4%) 88 (9.8%) 39 (7.7%) 29 (12.4%) 255 (9.1%)
ER status Negative 141 (12.0%) 117 (13.0%) 74 (14.6%) 40 (17.2%) 372 (13.2%)
Positive 1002 (85.4%) 753 (83.8%) 414 (81.8%) 185 (79.4%) 2354 (83.7%)
Unknown 30 (2.6%) 29 (3.2%) 18 (3.6%) 8 (3.4%) 85 (3.0%)
HER2 status Negative 981 (83.6%) 724 (80.5%) 375 (74.1%) 192 (82.4%) 2272 (80.8%)
Inconclusive 9 (0.8%) 7 (0.8%) 4 (0.8%) 2 (0.9%) 22 (0.8%)
Positive 136 (11.6%) 115 (12.8%) 63 (12.5%) 18 (7.7%) 332 (11.8%)
Unknown 47 (4.0%) 53 (5.9%) 64 (12.6%) 21 (9.0%) 185 (6.6%)
Oncotype DX test performed No 212 (18.1%) 138 (15.4%) 76 (15.0%) 38 (16.3%) 464 (16.5%)
Yes 26 (2.2%) 13 (1.4%) 2 (0.4%) 0 (0.0%) 41 (1.5%)
Not Applicable 306 (26.1%) 265 (29.5%) 186 (36.8%) 75 (32.2%) 832 (29.6%)
Unknown 629 (53.6%) 483 (53.7%) 242 (47.8%) 120 (51.5%) 1474 (52.4%)
Charlson comorbidity index
(no age)
n 1133 869 481 224 2707
Mean (SD) 0.90 (1.21) 1.10 (1.36) 1.19 (1.37) 1.09 (1.30) 1.03 (1.30)
Median (IQR) 0.00 (0.00, 2.00) 1.00 (0.00, 2.00) 1.00 (0.00, 2.00) 1.00 (0.00, 2.00) 1.00 (0.00, 2.00)
Min, Max 0, 6 0, 9 0, 9 0, 6 0, 9
Charlson calculated 10-year
survival probabilitya
n 1133 869 481 224 2707
Mean (SD) 0.55 (0.28) 0.51 (0.29) 0.28 (0.24) 0.26 (0.23) 0.47 (0.29)
Median (IQR) 0.77 (0.21, 0.77) 0.53 (0.21, 0.77) 0.21 (0.02, 0.53) 0.21 (0.02, 0.53) 0.53 (0.21, 0.77)
Min, Max 0, 0.77 0, 0.77 0, 0.77 0, 0.53 0, 0.77
Number of concurrent
medications
n 973 801 462 210 2446
Mean (SD) 3.85 (2.66) 4.16 (2.63) 4.26 (2.63) 4.21 (2.53) 4.06 (2.64)
Median (IQR) 3.00 (2.00, 5.00) 4.00 (2.00, 6.00) 4.00 (2.00, 6.00) 4.00 (2.00, 6.00) 4.00 (2.00, 5.75)
Min, Max 0, 14 0, 18 0, 14 0, 14 0, 18
ADL category No dependency 924 (78.8%) 623 (69.3%) 331 (65.4%) 126 (54.1%) 2004 (71.3%)
Mild dependency 89 (7.6%) 109 (12.1%) 67 (13.2%) 43 (18.5%) 308 (11.0%)
Moderate/severe dependency 70 (6.0%) 101 (11.2%) 60 (11.9%) 47 (20.2%) 278 (9.9%)
Unknown 90 (7.7%) 66 (7.3%) 48 (9.5%) 17 (7.3%) 221 (7.9%)
IADL category No dependency 955 (81.4%) 679 (75.5%) 332 (65.6%) 103 (44.2%) 2069 (73.6%)
Mild dependency 54 (4.6%) 78 (8.7%) 70 (13.8%) 47 (20.2%) 249 (8.9%)
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matched to 350 who did not receive it. Supplementary Table 5
shows the characteristics of the matched dataset and the
matching process and quality are summarised in Supplementary
Fig. 1. Mortality status was available for 542 (99%) of the matched
patients. Chemotherapy was associated with a longer OS although
this was not statistically significant (HR 0.79 [95% CI 0.50–1.26, p=
0.320]) (Fig. 2b).
BCSS was available for 98% (1486/1520) of patients in the high-
risk population. Chemotherapy was not associated with improved
BCSS (unadjusted HR 0.76 [95% CI 0.53–1.10, p= 0.147] and
adjusted HR 0.92 [95% CI 0.56–1.53, p= 0.758]) (Fig. 2c). In the
propensity score-matched population, BCSS was available for 539
patients (98%). Chemotherapy was also not found to be
associated with improved BCSS (HR 0.93 [95% CI 0.52–1.66, p=
0.798]) (Fig. 2d).
Metastatic recurrence data were available for 1498 high-risk
patients (99%). Chemotherapy was associated with a significantly
lower risk of metastatic recurrence in the unmatched population
(unadjusted HR 0.67 [95% CI 0.43–1.04, p= 0.077] and adjusted HR
0.36 [95% CI 0.19–0.68, p= 0.002]) (Fig. 2e). In 541 matched
patients (98%), chemotherapy was also associated with a lower
metastatic recurrence risk (HR 0.53 [95% CI 0.26–1.07, p= 0.076])
(Fig. 2f).
Additional post-hoc exploratory analyses were performed in
disease subgroups. Out of 369 patients with ER-negative EBC and
known mortality status, 132 (35.8%) received chemotherapy. In a
propensity score-matched analysis in 136 patients, chemotherapy
was associated with better OS (HR 0.20 [0.08–0.49]) and BCSS (HR
0.12 [0.03–0.44]) (Fig. 3, Supplementary Table 6 and Supplementary
Fig. 2). Three hundred twenty six patients with HER2-positive EBC
and known mortality status of whom 156 (47.9%) received
chemotherapy with or without trastuzumab. Fewer deaths from
breast cancer and other causes occurred in those receiving
chemotherapy with or without trastuzumab. However, in a matched
analysis in 137 patients, the differences were not statistically
significant for OS (HR 0.63 [0.27–1.48]) or BCSS (HR 0.50 ([0.16–1.63])
(Fig. 3, Supplementary Table 6 and Supplementary Fig. 2).
Supplementary Table 7 outlines chemotherapy toxicity. Among
397 patients receiving chemotherapy, there was one
chemotherapy-related death (0.25%) (due to congestive heart
failure) and 132 (33.2%) had an episode of infection, which was
grade 3 or 4 in 50 (12.6%). Among the 163 patients who received
trastuzumab, 4 (2.5%) experienced cardiac failure within the first
6 months and 12 (6.7%) within the first year.
Among 2811 patients undergoing surgery, the QoL analysis was
restricted to 1520/2811 (54.1%) with high-risk EBC of whom 1315/
1520 (86.5%) had an EQ-5D-5L score available at baseline. Of these
patients, 376/1520 (24.7%) received chemotherapy. Health utilities
were similar with estimated mean differences less than 0.02 units
(p > 0.1), whereas the visual analogue scale (VAS) measures were
significantly worse at 6 months in patients receiving chemotherapy
versus not (adjusted mean difference −6.57, 95% CI −8.74 to −4.40,
p < 0.001). Changes were no longer significant at 12 months and
thereafter (Supplementary Table 8; Supplementary Fig. 3).
Table 1. continued
70–74 75–79 80–84 ≥85 All
N= 1173 N= 899 N= 506 N= 233 N= 2811
Moderate/severe dependency 67 (5.7%) 70 (7.8%) 55 (10.9%) 66 (28.3%) 258 (9.2%)
Unknown 97 (8.3%) 72 (8.0%) 49 (9.7%) 17 (7.3%) 235 (8.4%)
MMSE category Normal function 1059 (90.3%) 805 (89.5%) 444 (87.7%) 186 (79.8%) 2494 (88.7%)
Mild impairment 91 (7.8%) 74 (8.2%) 50 (9.9%) 33 (14.2%) 248 (8.8%)
Moderate impairment 11 (0.9%) 12 (1.3%) 5 (1.0%) 8 (3.4%) 36 (1.3%)
Severe 12 (1.0%) 8 (0.9%) 7 (1.4%) 6 (2.6%) 33 (1.2%)
APG-SGA category Low 929 (79.2%) 709 (78.9%) 370 (73.1%) 172 (73.8%) 2180 (77.6%)
Moderate 111 (9.5%) 88 (9.8%) 62 (12.3%) 27 (11.6%) 288 (10.2%)
High 15 (1.3%) 13 (1.4%) 10 (2.0%) 2 (0.9%) 40 (1.4%)
Unknown 118 (10.1%) 89 (9.9%) 64 (12.6%) 32 (13.7%) 303 (10.8%)
ECOG performance status 0 930 (79.3%) 619 (68.9%) 305 (60.3%) 90 (38.6%) 1944 (69.2%)
1 151 (12.9%) 205 (22.8%) 142 (28.1%) 109 (46.8%) 607 (21.6%)
2 21 (1.8%) 24 (2.7%) 23 (4.5%) 12 (5.2%) 80 (2.8%)
3 10 (0.9%) 9 (1.0%) 8 (1.6%) 9 (3.9%) 36 (1.3%)
4 1 (0.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.0%)
Unknown 60 (5.1%) 42 (4.7%) 28 (5.5%) 13 (5.6%) 143 (5.1%)
Breast surgery Wide local excision (non wire
localised)
769 (65.5%) 504 (56.1%) 236 (46.7%) 89 (38.2%) 1598 (56.8%)
Therapeutic mammoplasty/
breast reshaping after WLE
35 (3.0%) 12 (1.3%) 2 (0.4%) 2 (0.9%) 51 (1.8%)
Mastectomy 316 (26.9%) 346 (38.5%) 251 (49.6%) 136 (58.4%) 1049 (37.3%)
Mastectomy and reconstruction 25 (2.1%) 10 (1.1%) 2 (0.4%) 0 (0.0%) 37 (1.3%)
Other 10 (0.9%) 5 (0.6%) 5 (1.0%) 0 (0.0%) 20 (0.7%)
Unknown 18 (1.5%) 22 (2.4%) 10 (2.0%) 6 (2.6%) 56 (2.0%)
Axillary surgery Axillary sample 38 (3.2%) 30 (3.3%) 11 (2.2%) 9 (3.9%) 88 (3.1%)
Axillary clearance 134 (11.4%) 134 (14.9%) 99 (19.6%) 47 (20.2%) 414 (14.7%)
Sentinel lymph node biopsy 881 (75.1%) 633 (70.4%) 336 (66.4%) 130 (55.8%) 1980 (70.4%)
Internal mammary node biopsy 0 (0.0%) 1 (0.1%) 0 (0.0%) 0 (0.0%) 1 (0.0%)
No axillary surgery 23 (2.0%) 16 (1.8%) 22 (4.3%) 19 (8.2%) 80 (2.8%)
Unknown 97 (8.3%) 85 (9.5%) 38 (7.5%) 28 (12.0%) 248 (8.8%)
aTen-year survival calculated as 0.983^(eCCI × 0.9), where CCI Charlson Comorbidity Index.
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A similar pattern on EQ-5D-5L usual activities score was seen in
520 propensity score-matched patients (including 118 patients
receiving chemotherapy and 332 not receiving it) (Supplementary
Fig. 4).
DISCUSSION
This study represents one of the largest prospective cohort studies
conducted in older women with breast cancer and provides
valuable data on tumour characteristics and health of older EBC
patients. As expected, the majority of patients had relatively good
prognosis tumours, with relatively low rates of nodal involvement
and adverse biology as determined by ER and HER2 status.
Nonetheless, there remained a substantial proportion of high risk,
fit patients (on baseline assessments), with a high relapse risk in
their expected lifetime. Ensuring that these patients receive
adequate treatment is a priority for clinicians.
A key finding of this study is that 27.8% of fit high-risk EBC older
patients received chemotherapy. In the ACheW study 30% of high-
risk EBC patients were offered chemotherapy and 17% received
it.23 Analyses of European and US registry data report similar
findings.5,24,25 These analyses did not consider recurrence risk (as
determined by histopathological variables) and patients’ fitness
(to not only receive treatment but also to live long enough to
benefit). The current study overcame these limitations, by defining
recurrence risk and fitness, and still demonstrates low
Table 2. Relationship between chemotherapy use and patient characteristics: univariate (Table 2a) and multi-variable (Table 2b) analyses.
(a) Results for univariate logistic regression models.
Variable Level OR (95% CI) P-value
Age 0.84 (0.82, 0.87) <0.001
ADL score 1.07 (1.04, 1.11) <0.001
IADL score 1.77 (1.43, 2.25) <0.001
CCI (no age) 0.84 (0.77, 0.93) <0.001
APG-SGA 0.95 (0.89, 1.01) 0.127
Allred score 0.80 (0.78, 0.83) <0.001
Tumour grade Grade 1 – –
Grade 2 9.04 (3.78, 29.58) <0.001
Grade 3 37.67 (15.87, 122.76) <0.001
ER positive 0.22 (0.17, 0.28) <0.001
HER2 statusa Negative – –
Positive 8.49 (6.57, 10.97) <0.001
MMSE category Normal function – –
Mild impairment 0.75 (0.49, 1.11) 0.172
Moderate impairment 1.18 (0.44, 2.67) 0.711
Severe 0.38 (0.06, 1.27) 0.188
Nodal statusb pN0-1mi – –
pN1 2.18 (1.69, 2.80) <0.001
pN2 5.05 (3.47, 7.29) <0.001
pN3 6.42 (3.96, 10.30) <0.001
(b) Results from the multi-variable logistic regression model.
Variable Level OR (95% CI) P-value
Age 0.74 (0.71, 0.78) <0.001
IADL score 1.97 (1.53, 2.63) <0.001
CCI (no age) 0.83 (0.73, 0.95) 0.007
Tumour grade Grade 1 – –
Grade 2 8.42 (3.05, 34.90) <0.001
Grade 3 29.50 (10.59, 123.00) <0.001
ER positive 0.19 (0.13, 0.28) <0.001
HER2 status Negative – –
Positive 8.94 (6.19, 13.01) <0.001
Nodal status pN0-1mi
pN1 4.01 (2.81, 5.75) <0.001
pN2 11.24 (6.43, 19.74) <0.001
pN3 8.84 (4.31, 18.05) <0.001
aTests marked as ‘Inconclusive’ were removed from this analysis.
bThose with nodal status pNx were removed from this analysis.
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chemotherapy uptake. This may be due to uncertainty on
chemotherapy benefit in older adults, toxicity concerns and
patients’ and carers’ choice.
In order to investigate the survival benefits of chemotherapy for
older EBC patients, we conducted survival analyses in those at
high risk of recurrence. Ideally this question should be addressed
by RCTs. Recruiting older patients into RCTs comparing different
chemotherapy regimens is feasible,26 but trials comparing
chemotherapy with no chemotherapy have failed to recruit.27,28
Moreover, older patients enrolled in RCTs may be fitter and not
necessarily representative of a real-world population.6 In contrast,
this cohort study recruited well, and recruited patients with a
broad fitness range.
Our analyses attempted to correct for confounders, specifically
the fact that younger, fitter patients might be more likely to
receive chemotherapy, but also are biologically more likely to
survive longer irrespective of chemotherapy effect. This effect is
perhaps most apparent when comparing the unmatched and
matched OS analyses (Fig. 2a, b).
In the high-risk population chemotherapy reduced the risks of
metastatic recurrence, which did not translate into better survival.
This may be because the benefit was modest and the fact that
median OS for ER-positive metastatic disease patients often
exceeds 3 years with contemporary therapies.29 Irrespective, a
reduction in metastatic relapses, with their symptomatic,
psychological and financial implications, may be sufficient
grounds on which to offer treatment even in the absence of a
survival benefit. Longer term follow-up will be required to further
explore this.
Chemotherapy benefits are small for most ER-positive, HER2-
negative EBC patients. Therefore, we performed exploratory analyses
in patients with the more chemotherapy-sensitive subtypes, i.e. ER-
negative and HER2-positive disease. In ER-negative EBC patients
there was an apparent reduction of breast cancer deaths with
chemotherapy. These data are consistent with an US SEER analysis
suggesting that adjuvant chemotherapy benefit in older patients
were restricted to those with ER-negative disease.28,30 In HER2-
positive EBC patients, fewer breast cancer deaths occurred in those
who received chemotherapy with or without trastuzumab although
the differences were not statistically significant in a matched
analysis. This could be explained by the small numbers in this
subgroup analysis. However, a retrospective study demonstrated
that HER2-positive EBC older patients do not have inferior long-term
outcomes compared with younger adults not receiving chemother-
apy.31 Low Ki67 and high bcl2 expression in the older cohort of
HER2-positive patients might explain this better prognosis and also
relative chemo-resistance.31
Our study found that mortality rates from chemotherapy were
very low and side effects consistent with previous analyses.32
Follow-up of the cohort is planned at 10 years and may provide
data about longer term benefits, although it should be recognised
that with longer follow-up competing mortality causes are likely
have a greater impact.
Our analysis also demonstrates that chemotherapy has a
significant negative impact at 6 months on QoL, which is a
meaningful endpoint in the context of a more limited survival
benefit and increased risk of toxicities in this population.
However, this effect resolves at 12 months consistent with
previous findings in smaller or younger cohorts of patients33,34
and is described in a more extensive analysis performed on this
patient cohort.18
A key strength of this study is that patients were recruited from
a broad range of academic and general centres across the UK, and
were likely to reflect contemporary practice and outcomes.
However, despite the inclusive entry criteria and low level of
intervention there was still the possibility of selection bias. In a
separate analysis of this study we found that patients who did not
enter the trial following screening were older and had worse
functional ability.35 Also, as patients were not randomised,
unmeasured variables might have influenced our findings despite
Table 3. Chemotherapy use according to risk of recurrence and fitness.
(a) Use of chemotherapy by risk status.
Risk Chemotherapy No Chemotherapy Total
High risk 376 (24.7%) 1144 (75.3%) 1520 (100.0%)
Non-high risk 21 (1.6%) 1270 (98.4%) 1291 (100.0%)
Total 397 (14.1%) 2414 (85.9%) 2811 (100.0%)
(b) Use of chemotherapy by fitness.
Fitness Chemotherapy No Chemotherapy Total
Fit 322 (15.6%) 1737 (84.4%) 2059 (100.0%)
Vulnerable 75 (10.0%) 675 (90.0%) 750 (100.0%)
Frail 0 (0.0%) 2 (100.0%) 2 (100.0%)
Total 397 (14.1%) 2414 (85.9%) 2811 (100.0%)
(c) Use of chemotherapy by risk and fitness.
Fitness High risk Non-high risk Total
Chemotherapy No chemotherapy Chemotherapy No chemotherapy
Fit 306 (14.9%) 794 (38.6%) 16 (0.8%) 943 (45.8%) 2059 (100.0%)
Vulnerable 70 (9.3%) 349 (46.5%) 5 (0.7%) 326 (43.5%) 750 (100.0%)
Frail 0 (0.0%) 1 (50%) 0 (0.0%) 1 (50%) 2 (100%)
Total 376 (13.4%) 1144 (40.7%) 21 (0.7%) 1270 (45.2%) 2811 (100.0%)
Bold values represent the total numbers for each column or row.
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propensity score matching. The extent to which these data reflect
practice and outcomes outside of the UK is unknown, although
some published data do appear comparable.24,25
In summary, this study demonstrates that there are a significant
number of older but fit patients with high-risk EBC who are not
receiving adjuvant chemotherapy. Some of these patients,
particularly those with ER-negative disease, may derive benefit
from chemotherapy. Clearly the benefits need to be discussed in
the context of potential side effects and the transient negative
impact on QoL. Nonetheless, it is important that individualised
treatment decisions and discussions are made to ensure the best
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Fig. 2 Kaplan–Meier plots of survival and metastatic recurrence outcomes. a Overall Survival in unmatched high-risk patients (n = 1495).
Adjusted HR 0.87 (95% CI 0.58–1.28, p= 0.47). b Overall survival in matched high-risk patients (n= 542). Adjusted HR 0.79 (95% CI: 0.50–1.26,
p= 0.32). c Breast cancer-specific survival in unmatched high-risk patients (n= 1486). Adjusted HR 0.92 (95% CI: 0.56–1.53, p= 0.76). d Breast
cancer-specific survival in matched high-risk patients (n= 539). Adjusted HR 0.93 (95% CI: 0.52–1.66, p= 0.80). e Metastatic recurrence in
unmatched high-risk patients (n= 1498). Adjusted HR 0.36 (95% CI: 0.19–0.68, p= 0.002). fMetastatic recurrence in matched high-risk patients
(n= 541). Adjusted HR 0.53 (95% CI: 0.26–1.07, p= 0.08).
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